The HKU Scholars Hub   The University of Hong Kong   香港大學學術庫

Title	**Increase in the nasopharyngeal carriage of non-vaccine serogroup 15 Streptococcus pneumoniae after introduction of children pneumococcal conjugate vaccination in Hong Kong**
Author(s)	**Ho, PL; Chiu, SSS; Law, PYT; Chan, ELY; Lai, ELY; Chow, KH**
Citation	**Diagnostic Microbiology and Infectious Disease, 2015, v. 81 n. 2, p. 145-148**
Issued Date	**2015**
URL	**http://hdl.handle.net/10722/213732**
Rights	

1 **Increase in the nasopharyngeal carriage of non-vaccine serogroup 15 *Streptococcus***

2 ***pneumoniae* after introduction of children pneumococcal conjugate vaccination in Hong**

3 **Kong**

4

5 Pak-Leung Ho[1*], Susan S. Chiu[2], Pierra Y. Law[1], Eunice L. Chan[1], Eileen L. Lai, Kin-Hung

6 Chow[1]

7 [1]*Department of Microbiology and* [2]*Department of Paediatrics and Adolescent Medicine, The*

8 *University of Hong Kong, Pokfulam Road, Hong Kong Special Administrative Region,*

9 *CHINA*

10

12 *corresponding author: Division of Infectious Diseases, Department of Microbiology and

13 Centre of Infection, The University of Hong Kong, Queen Mary hospital, Pokfulam Road,

14 Pokfulam, Hong Kong SAR, CHINA. Tel.: +852-2855 4897; fax: +852-2855 1241.

15 *E-mail address*: plho@hkucc.hku.hk (P. L. Ho).

16
17

18   **Abstract**

19   This study assessed pneumococcal carriage in the early periods after routine use of 13-valent

20   pneumococcal conjugate vaccine (PCV13) in Hong Kong. Nasopharyngeal swabs were

21   obtained from 1110 children (<5 years) admitted with acute illness during September

22   2010-August 2013. Pneumococcal carriage rate was 13.5% in unvaccinated children, 14.1%

23   in children who had ≥1 PCV dose and 15.3% in children who had ≥3 PCV doses.

24   Nonv-PCV13 serotypes comprised 56.4% of all isolates. The most common serogroup/types

25   were 15 (15A, 5.1%; 15B, 10.3%; 15C, 9.6%; 15F, 0.6%), 19F (17.9%), 6A (7.1%) and 6C

26   (7.1%). Carriage of serogroup 15 was more common among vaccinated children (4.1% vs.

27   0.6%, P=0.033). Molecular typing revealed that expansion of several clones (clonal complex,

28   CC63, CC199, CC1262, CC3397) was responsible for the increase in serogroup 15. Almost

29   all CC63 and CC3397 isolates were nonsusceptible to both penicillin and erythromycin. The

30   finding highlights the emergence of serogroup 15 following PCV13 use.

31
32   (150 words)
33
34

Introduction

Routine use of 7-valent pneumococcal conjugate vaccine (PCV-7) has been followed by reductions in vaccine serotypes invasive pneumococcal disease (IPD) and nasopharyngeal carriage among children targeted for vaccination (Ho et al., 2006; Ho et al., 2011b; Miller et al., 2011). The IPD rates have also reduced in older children and adults through herd immunity (Miller et al., 2011). However, these benefits have been counteracted by increased rates of IPD and carriage with non-PCV7 serotypes, notably multidrug-resistant 19A (Moore et al., 2008). However, the factors affecting serotype replacement are complex (Mehr and Wood, 2012; Dagan, 2009). Post-PCV7 surveillances have found variability in the pace of serotype replacement and in the predominating nonvaccine serotypes (Mehr and Wood, 2012). Broader coverage is provided by the 10-valent and 13-valent pneumococcal conjugate vaccines (PCV10 and PCV13) which were first approved by the European Medicines Agency in January 2009 and by the Food and Drug Administration in the United States in February 2010, respectively for use in children. In addition to the seven serotypes included in PCV7 (4, 6B, 9V, 14, 18C, 19F and 23F), PCV10 contains serotypes 1, 5, 7F, and PCV13 contains 1, 3, 5, 6A, 7F and 19A. PCV13 has been approved in 128 countries and at least 83 of them have put PCV13 into routine use for children (Chiba et al., 2014). Concerns have been raised that increasing use of PCV13 would drive a shift towards non-PCV13 serotypes in both IPD and carriage (Mehr and Wood, 2012). Nonetheless, information on the changes in serotype

54   distribution and antimicrobial susceptibilities of pneumococcal isolates in the post-PCV13 era

55   is limited (Chiba et al., 2014; Zuccotti et al., 2014).

56   In Hong Kong, PCV7 has been available in the market since October 2005 (Ho et al.,

57   2011a). PCV10 and PCV13 were later marketed in August 2009 and May 2010, respectively.

58   In Asia, Hong Kong is one of the first cities to introduce PCV7 into the childhood

59   immunization program and this was implemented since September 2009 (Ho et al., 2011a).

60   From October 2010 onward, PCV7 was replaced by PCV10. This was mainly driven by

61   vaccine cost consideration and the non-inferior safety and efficacy of PCV10 against IPD,

62   when compared to PCV7. From December 2011 onward, PCV10 was replaced by PCV13

63   (Ho et al., 2011b). No catch-up vaccination was arranged at the time of switching to PCV10

64   and PCV13. For all formulations, the immunization schedule consists of a standard

65   three-dose primary series (at 2, 4 and 6 months of age) and a booster dose at age 12-15

66   months. Before its routine use in our children, PCV7 was available as a self-financed item

67   and its uptake in the vaccine target population had been low (Ho et al., 2011b). Here, we

68   investigated the further changes in pneumococcal carriage and of the serotypes and

69   antimicrobial resistance in children aged <5 years from 2010 to 2013.

70

71   **2. Materials and method**

72   *2.1 Study design and data collection*

73   Nasopharyngeal swabs were collected from children aged <5 years hospitalized in a

74   regional hospital from September 2010 to August 2013. A standardized questionnaire was

75   used to obtain the following participant information from parents of participating children:

76   demographic characteristics, number of siblings (and their ages), day care attendance, prior

77   antibiotic treatment (in the last 3 months), current antibiotic treatment, smoking habit of

78   family members, the physician's diagnosis on the screening day, medical and immunization

79   history (PCV7, PCV10 and PCV13). Young children aged <5 years who were hospitalized

80   for acute illness (e.g. respiratory illness, diarrhea) were enrolled. Children with major

81   underlying condition (e.g. immunosuppression, malignancy, chronic heart disease, chronic

82   lung disease, chronic renal disease, diabetes mellitus) were excluded. The protocol is

83   approved by the Institutional Review Board at the Hong Kong West Cluster/University of

84   Hong Kong.

85   *2.2 Microbiological methods*

86   Nasopharyngeal cultures were obtained with alginate-tipped swabs (Ho et al., 2011b).

87   All specimens were obtained by trained nurses. The swabs were transferred to the

88   microbiology laboratory at the University of Hong Kong within 6 hours of collection in

89   Amies transport media (TRANSWAB per nasal; Medical Wire and Equipment, Wilts, United

90   Kingdom). For selective isolation of *S. pneumoniae*, nasopharyngeal swabs were inoculated

91   onto 5% horse blood agar supplemented with gentamicin (2 μg/ml) and incubated in 5% CO_2

92 for 16 to 24 hours. The isolates were identified by colony morphology, Gram stain, optochin

93 susceptibility, bile solubility and a slide co-agglutination test (Phadebact Pneumococcus Test,

94 Remel). Susceptibility of the isolates was determined by Etest (penicillin, cefotaxime) or disc

95 diffusion method (erythromycin) (Clincal and Laboratory Standard Institute, 2014). The

96 criteria for penicillin-nonsusceptible and cefotaxime-nonsusceptible were $\geq 0.12\mu g/ml$ (oral

97 penicillin breakpoint) and $\geq 2\mu g/ml$ (nonmeningitis breakpoint).

98 *2.3 Molecular studies*

99 The serotypes of the *S. pneumoniae* isolates were determined by multiplex PCR and the

100 Quellung reaction (Ho et al., 2011a; Ho et al., 2011b). The isolates were initially tested by a

101 sequential multiplex PCR approach (Pai et al., 2006). Strains that could not be serotyped and

102 those that required further testing to the serotype level were then tested by the Quellung

103 method with group, type and factor antisera from the Statens Seruminstitut (Copenhagen,

104 Demark). Serotype 6C and 6D were identified by PCR assays (Ho et al., 2010). Multilocus

105 sequence   typing   (MLST)   was   performed   as   previously   described

106 (http://pubmlst.org/spneumoniae/) and results were analyzed by eBURST v3 (Enright and

107 Spratt, 1998).

108 *2.4 Statistical analysis*

109 The serotype coverage for the 7-valent and 13-valent PCVs for carriage isolates was

110 calculated as the proportion of all isolates included in the vaccine formulations, without

111 taking into account the potential serogroup cross-protection. Potential risk factors for

112 pneumococcal carriage were studied by univariate analysis using Chi square or Student's *t*

113 test. Variables that were significant in the univariate analysis and those that could increase

114 the risk of carriage from a clinical point of view were further tested by logistic regression

115 using the forward-conditional models. The following parameters were entered for analysis in

116 the logistic regression models: age, gender, having sibling aged <5 years, having smoker in

117 household, day care center (DCC) attendance, recent antibiotic use and any use of PCV. To

118 further understand how pneumococcal carriage might have changed before and at different

119 time periods after implementation of PCVs, selected data from this study was tabulated with

120 those from two previous studies conducted by us (Chiu et al., 2001; Ho et al., 2011b). A *P*

121 value of <0.05 was considered to indicate statistical significance. All statistical analysis was

122 performed by the SPSS statistic package (version 20.0, SPSS Hong Kong Ltd., Hong Kong).

123

124 **3. Results**

125 *3.1 Demographics*

126   A total of 1110 children were enrolled in the study. The mean age (± standard deviation

127 [SD]) of the children was 1.7 ± 1.2 years. The mean ± SD household size was 3.6 ± 1.3.

128 Fifty-eight percent of the children were male. In this cohort of children, 29.6% had household

129 siblings aged ≤5 years; 53.4% had recent antibiotic use; 27.6% had exposure to household

130 smokers and 86.0% had at least one dose of any PCVs (79.7% in 2010/2011, 86.3% in

131 2011/2012 and 95.2% in 2012/2013). Among vaccinated children, 44.1% had ≥1 dose PCV7,

132 39.1% had ≥1 dose PCV10, 29.9% had ≥1 dose PCV13 and 67.7% had ≥3 doses of any PCVs.

133 Combination of >1 PCV formulations was received by 24.9% of the vaccinated children.

134 *3.2 Pneumococcal serotype distribution and antimicrobial susceptibilities*

135 Pneumococcal carriage was detected in 14.1% (156/1110) of the children (16.7% in

136 2010/11, 12.5% in 2011/12, and 12.5% in 2012/13). Table 1 showed distribution of the

137 serotypes and antimicrobial resistance. Overall, PCV13 serotypes accounted for 43.6%

138 (68/156) and non-vaccine serotypes accounted for 56.4% (88/156). Four PCV13 serotypes

139 including 1, 7F, 9V and 18C were not found. The common serotypes were 19F (17.9%), 15B

140 (10.3%), 15C (9.6%), 6A (7.1%) and 6C (7.1%). Serogroup 15 accounted for 45.5% (40/88)

141 of all non-vaccine isolates (including 15A, 9.1% [8/88]; 15B, 18.2% [16/88]; 15C, 17.0%

142 [15/88] and 15F, 1.1% [1/88]). MIC_{50}/MIC_{90} (range) of penicillin and cefotaxime for all the

143 isolates were 0.125/4 µg/ml (0.002–4 µg/ml) and 0.125/4 µg/ml (0.008–16 µg/ml),

144 respectively. Isolates with penicillin (MIC ≥0.12µg/ml), cefotaxime (MIC ≥2µg/ml),

145 erythromycin and dual penicillin/erythromycin nonsusceptibility were found among a wide

146 range of different serotypes (Table 1). Eighteen isolates had penicillin MIC ≥4 µg/ml. They

147 belong to serotypes 19F (n=11), 19A (n=2), 15C (n=2), 15B (n=1), 6C (n=1) and 34 (n=1).

148

149   *3.3 Changes in serotypes of carried pneumococci over time*

150   The data from this study was tabulated with those from two previous studies (Table 2).

151   Compared to the previous two groups of children, there was a small decline in overall

152   pneumococcal carriage and antibiotic-resistant pneumococcal carriage rates. Prevalence of

153   PCV7 serotypes progressively declined. In contrast, pneumococcal isolates of non-PCV13

154   serotypes, especially serogroup 15 have increased in prevalence over time (Table 2). Within

155   the three years in period 3, no significant trends in serotype replacement were observed. The

156   prevalence of carriage of serogroup 15 was 3.6% in 2010/2011, 3.3% in 2011/2012 and 4.0%

157   in 2012/2013 (P=0.883). Serogroup 15 accounted for 21.7% of all pneumococcal isolates in

158   2010/2011, 26.4% in 2011/2012 and 32.4% in 2012/2013 (P=0.504).

159

160   *3.4 Pneumococcal carriage and PCV use*

161   In the current cohort (period 3), total pneumococcal carriage was not associated with

162   pneumococcal immunization status. Carriage rate was 13.5% in unvaccinated children, 14.1%

163   in children who had ≥1 PCV dose ($P = 0.845$) and 15.3% in children who had ≥3 PCV doses

164   ($P = 0.437$). The effect of PCVs on pneumococcal carriage was further investigated by

165   multivariate analysis. A history of PCV use was independently associated with lower carriage

166   of PCV7 serotypes (P=0.042; odds ratio [OR], 0.5; 95% confidence interval [CI], 0.2 to 0.9)

167   and higher carriage of non-PCV13 serotypes (P=0.025; OR, 2.9; 95% CI, 1.1 to 7.2).

168   Carriage of serogroup 15 was significantly more common among children with a history of

169   PCV use (4.1% [39/955] vs. 0.6% [1/155], *P*=0.033). However, the association failed to

170   reach statistical significance in the multivariate analysis (*P*=0.064, OR, 6.6; 95% CI, 0.9 to

171   48.1).

172

173   *3.5 Changes in antimicrobial resistance and clonal structure of serogroup 15 isolates*

174   A total of 82 serogroup 15 isolates (serotype 15A, 17 isolates; 15B, 26 isolates; 15C, 35

175   isolates; and 15F, 4 isolates) were obtained during the three time periods and all were

176   investigated by MLST. The relationship between MLST and serogroup 15 subtypes was

177   summarized in Table 3. An eBURST analysis of our isolates with all other serogroup 15

178   isolates in the MLST database was shown in Figure S1 (supplementary file). In the three time

179   period, either 15C or 15B was the most prevalent subtype. The isolates belonged to 24

180   different sequence types (STs) of which 68 isolates belonged to five clonal complexes (CCs,

181   with 6 to 27 isolates each) and 14 isolates were singletons (12 different STs). The prevalence

182   of four clones had increased over time (Figure 1): CC199-serotype 15B/C clone, 1.3%, 2.6%

183   and 8.3% (*P* < 0.001); CC1262-serotype 15B/C clone, 0%, 0.9% and 6.4% (*P*<0.001);

184   CC63-serotype 15A/C/F clone, 0.3%, 1.4% and 5.8% (*P* < 0.001); and CC3397-serotype

185   15B/C clone, 0%, 0.6% and 2.6% (*P* = 0.004) in period 1, period 2 and period 3, respectively.

186   The nonsusceptibility rates among serogroup 15 isolates from period 1, period 2 and period 3

187   were 7.1%, 32.1% and 37.5% for penicillin (P = 0.102), 50.0%, 57.1% and 47.5% for

188   erythromycin (P = 0.732), and 7.1%, 32.1% and 30.0% (P = 0.185) for dual

189   penicillin/erythromycin nonsusceptibility, respectively. The penicillin- and

190   erythromycin-nonsusceptibility rates by clonal groups were as follows: CC199-serotype

191   15B/C, 11.1%/18.5%; CC63-serotype 15A/C/F, 80%/100%; CC1262-serotype 15B/C,

192   7.7%/15.4%; CC156-serotype 15A/C/F, 14.3%/57.1%; CC3397-serotype 15B/C,

193   100%/100% and singletons, 14.3%/71.4%. High level penicillin resistance (MIC ≥4 μg/ml)

194   was observed in four isolates, three from period 3 and one from period 2. The isolates

195   belonged to ST3397-serotype 15C (n=2), ST199-serotype 15B (n=1) and ST1262-serotype

196   15C (n=1).

197

198   **4. Discussion**

199   This study extends our previous observations on the changes in pneumococcal carriage,

200   antimicrobial resistance rates and serotype distribution of nasopharyngeal isolates before and

201   since the routine use of PCVs in our children (Ho et al., 2011b). The findings showed that

202   overall carriage declined and was due mainly to a loss of PCV7 serotypes. At the same time,

203   there was replacement with non-vaccine serotypes. We previously noted an increase in

204   several PCV13-nonPCV7 (6A and 19A) and nonPCV13 serogroup/serotypes (6C, 23A and

205   15) among children from period 2 (Ho et al., 2011b). Here, we found that the incidences of

206   6A, 19A and 6C have declined or stabilized following a switch to PCV13 for routine use.

207   Of note, serogroup 15 isolates continued to rise and it is now the predominant colonizing

208   serogroup/serotype. When all the subtypes of serogroup 15 are considered together, their

209   prevalence had increased by 6.9 folds from 3.7% in 1999-2000 to 8.1% in 2009-2010 and

210   25.6% in 2010-2013. In serially sampled Massachusetts communities, 15B/C had increased

211   from 6% in 2001 to 11% in 2008-2009 following the widespread use of PCV7 (Wroe et al.,

212   2012). Among Pittsburgh-area's children presenting with acute otitis media (Martin et al.,

213   2014), an increase in the carriage of serogroup 15 pneumococci was also noted. In 2012-2013

214   (Martin et al., 2014), serogroup 15 (all subtypes) was the most frequently occurring

215   serogroup/serotype comprising 23% of all colonizing pneumococcal isolates. At present, the

216   clinical significance of the emergence of serogroup 15 in NP carriage is unclear. Previous

217   studies found that serotype 1, 3, 5, 7F and 19A (total 7.7% in this study) have a high

218   propensity to cause invasive disease while the ability of serogroup 15 to cause invasive

219   disease is low (Del et al., 2014; Yildirim et al., 2010). In the post-PCV13 era, only small

220   numbers of invasive pneumococcal disease were caused by serogroup 15 (Levy et al., 2014).

221   In Japan where PCV7 vaccination in children began in 2010, an increase in the rate of

222   pediatric invasive pneumococcal disease caused by 15A, 15B and 15C during 2010-2012 was

223   noted (Chiba et al., 2014). In our locality, ongoing surveillance has not detected any increase

224   in the frequency of occurrence of serogroup 15 among children with invasive pneumococcal

225   disease (Ho et al., 2011a).

226   Genotypic analysis of the serogroup 15 strains by MLST revealed that increasing

227   prevalence of serogroup 15 was mainly caused by expansion of several preexisting clones

228   (CC63-serotype 15A/C/F, CC199-serotype 15B/C, CC1262-serotype 15B/C and

229   CC3397-serotype 15B/C). Two of them, CC63-serotype 15A/C/F and CC199-serotype 15B/C

230   are internationally recognized clones designated by the Pneumococcal Molecular

231   Epidemiology Network (http://web1.sph.emory.edu/PMEN/pmen_table1.html) as

232   Sweden[15A]-25/ST63 and Netherlands[15B]-37/ST199, respectively. In the MLST database (last

233   accessed 25 August 2014) CC/ST63 and CC/ST199 are the commonest genotypes associated

234   with serotype 15A and 15B/C, respectively. Besides serogroup 15 subtypes, ST63 was also

235   commonly associated with serotype 14, 19A and 19F, and ST199 associated with serotypes 3,

236   6, 19A, 19F, 23A and 23F. Prior to the introduction of PCV13, ST199 is one of the major

237   STs involved in the massive expansion of serotype 19A (Scott et al., 2012). ST1262 and

238   ST3397 are minor genotypes among serogroup 15 strains in the MLST database. All ST3397

239   strains deposited in the database were of serogroup 15 and all were recovered from patients in

240   China (Li et al., 2011). As suggested previously (Scott et al., 2012), some STs may be

241   preferentially favored in serotype replacement. This could occur as existing clones switch

242   their capsules or by expansion of preexisting STs with nonvaccine serotypes (Croucher et al.,

243   2013).

244   This study has some potential limitations. First, we studied a convenient sample of

245   children hospitalized to a regional hospital. The fact that many children had history of recent

246   antibiotic use may influence the results of this study. Therefore, caution is required in

247   interpreting the findings involving comparisons with results from our previous territory-wide

248   carriage studies (Chiu et al., 2001; Ho et al., 2011b). Second, the number of children with

249   carriage was relatively small. Therefore, it was not possible to stratify the findings by age

250   groups. Third, the methodology that we adopted for culture is not capable of detecting

251   carriage of multiple serotypes. The strengths of this study include molecular typing of the

252   serogroup 15 isolates, and analysis of the culture result against the vaccination history and

253   other epidemiological data.

254   In conclusion, this study showed that nasopharyngeal carriage by previously prevalent

255   pneumococcal vaccine serotypes have largely been replaced by non-PCV13 types, especially

256   serogroup 15. The results demonstrate that expansion of preexisting clones was mainly

257   responsible for the recent increase in serogroup 15. Future pneumococcal vaccines may need

258   to be planned according to increasing serogroup 15.

259

260   **Acknowledgements**

268 Table 1

269 Distribution of antimicrobial non-susceptible nasopharyngeal *Streptococcus pneumoniae*

270 isolates according to serotypes, Hong Kong 2010-2013

	Total		%. with resistance phenotype[d]			
	%	n	Pen-NS	Ctx-NS	Ery-NS	Pen/Ery-NS
PCV13 types[a]						
19F	17.9	28	78.6	53.6	92.9	71.4
6A	7.1	11	63.6	0	100	63.6
19A	5.1	8	87.5	37.5	87.5	87.5
14	4.5	7	100.0	0	85.7	85.7
23F	3.8	6	50.0	0	66.7	50.0
6B	1.9	3	66.7	0	100	66.7
3	1.9	3	0	0	33.3	0
4	0.6	1	0	0	100.0	0
5	0.6	1	0	0	0	0
Non-PCV13 types						
15B	10.3	16	18.8	6.3	25.0	6.3
15C	9.6	15	46.7	13.3	40.0	40.0
6C	7.1	11	81.8	18.2	81.8	72.7
15A	5.1	8	50.0	12.5	100.0	50.0
23A	3.2	5	60.0	0	100.0	60.0
34	2.6	4	75.0	25.0	25.0	25.0
35B	2.6	4	50.0	0	0	0
11D	1.3	2	0	0	50.0	0
28A	1.3	2	0	0	100.0	0
35A/C/42	1.3	2	0	0	100.0	0
35F	1.3	2	0	0	50.0	0
15F	0.6%	1	100.0	0.0	100.0	100.0
Others[b]	5.1	8	0	0	50.0	0
NT	5.1	8	37.5	0	62.5	37.5
Total	100.0	156	53.2	16.0	69.2	46.2

271 [a] PCV7 serotypes were underlined. Four PCV13 serotypes including 1, 7F, 9V and 18C were

272 not found.

273 [b] Including one isolate each of the following eight serotypes: 11A, 13, 17F, 18A, 21, 22F, 29

274 and 33F.

275 [d] Penicillin-nonsusceptible (Pen-NS, MIC $\geq 0.12\mu g/ml$), cefotaxime-nonsusceptible (Ctx-NS,

276 MIC $\geq 2\mu g/ml$); erythromycin-nonsusceptible (Ery-NS); dual penicillin/erythromycin

277 -nonsusceptible (Pen/Ery-NS).

16

278 Table 2

279 Comparison of selected characteristics of children and nasopharyngeal *Streptococcus*

280 *pneumoniae* carriage, Hong Kong

	Sampling time[a]			P value[b]
	Period 1	Period 2	Period 3	
No. of children tested	1978	2221	1110	-
Recent antibiotic use, %	50.1	30.6	53.4	<0.001
Children with at least one dose of				
Any PCVs, %	0.0	28.1	86.0	<0.001
PCV13, %	0.0	0.0	25.8	<0.001
Children with pneumococcal carriage, %				
Any serotypes	19.4	15.6	14.1	<0.001
PCV7 serotypes	12.8	8.6	4.1	<0.001
PCV13-nonPCV7 serotypes	1.3	2.5	2.1	0.019
Non-PCV13 serotypes	5.3	4.6	7.9	<0.001
Serotype 6C	0.4	1.2	1.0	<0.001
Serogroup 15	0.7	1.3	3.6	<0.001
Antibiotic- resistant pneumococcal carriage, %				
Pen-NS	11.3	11.1	7.5	0.428
Ery-NS	14.9	13.6	9.7	0.266
Total no. of pneumococcal isolates	383	347	156	-
Proportion of pneumococci, % all isolates				
PCV7 serotypes	66.1	54.8	28.8	<0.001
PCV13-nonPCV7 serotypes	6.5	15.9	14.7	<0.001
Non-PCV13 serotypes	27.4	29.4	56.4	<0.001
Serotype 6C	1.8	7.8	7.1	0.001
Serogroup 15	3.7	8.1	25.6	<0.001

281 [a] Data for period 1 and period 2 were from two previous carriage studies involving healthy

282 children aged ≤5 years attending kindergartens or day care centers (Ho et al., 2011b; Chiu et

283 al., 2001) while period 3 involved children hospitalized in a regional hospital. The sampling

284 times were as follows: period 1, December 1999-June 2000; period 2, September 2009-April

285 2010; and period 3, September 2010-August 2013.

286 [b] Chi Square for comparison of data in the three time periods.

287

288

289   Table 3

290   Subtypes of serogroup 15 by pneumococcal clones and collection periods, Hong Kong

| Variable	n	Serotype, % by row			
		15A	15B	15C	15F
Collection time					
Period 1	14	21.4	7.1	50.0	21.4
Period 2	28	21.4	32.1	46.4	0.0
Period 3	40	20.0	40.0	37.5	2.5
Clones					
CC199[a]	27	0.0	48.1	51.9	0.0
CC63	15	80.0	0.0	6.7	13.3
CC1262	13	0.0	46.2	53.8	0.0
CC156	7	57.1	0.0	14.3	28.6
CC3397	6	0.0	16.7	83.3	0.0
Singletons[b]	14	7.1	42.9	50.0	0.0
Total	82	20.7	31.7	42.7	4.9

291   CC, clonal complex; ST, sequence type

292   [a] The following STs were found in the CCs.: CC199 (ST199, 22 isolates; ST200, 3 isolates;

293   ST1200, 1 isolate; ST9763, 1 isolate), CC63 (ST63, 15 isolates); CC1262 (ST1262, 13

294   isolates); CC156 (ST2647, 2 isolates; ST5453, 2 isolates; ST6011, 1 isolate; ST1078, 1

295   isolate; ST3280, 1 isolate); CC3397 (ST3397, 6 isolates).

296   [b] Two STs (ST8914 and ST9765) has two isolates each. Ten STs had one isolate each: ST83,

297   ST193, ST1835, ST2758, ST8496, ST9762, ST9764, ST9766, ST9767 and ST9768.

298   New STs found for the first time in this study were underlined.

299

300 Figure 1
301 Changes in the prevalence of *Streptococcus pneumoniae* serogroup 15 isolates according to
302 clonal complexes and sampling periods, Hong Kong. The sampling times were as follows:
303 period 1, December 1999-June 2000; period 2, September 2009-April 2010; and period 3,
304 September 2010-August 2013. The serotypes of the clonal complexes (CCs) were labeled.
305

306
307
308
309

310 **References**

311 Chiba N, Morozumi M, Shouji M, Wajima T, Iwata S, Ubukata K. Changes in capsule and

312 drug resistance of pneumococci after introduction of PCV7, Japan, 2010-2013. Emerg

313 Infect Dis 2014;20:1132-1139.

314 Chiu SS, Ho PL, Chow FK, Yuen KY, Lau YL. Nasopharyngeal carriage of

315 antimicrobial-resistant *Streptococcus pneumoniae* among young children attending 79

316 kindergartens and day care centers in Hong Kong. Antimicrob Agents Chemother

317 2001;45:2765-2770.

318 Clincal and Laboratory Standard Institute. Performance standards for antimicrobial

319 susceptibility testing: Twenty-fourth informational supplement M100-S24. Wayne, PA,

320 Clincal and Laboratory Standard Institute, 2014.

321 Croucher NJ, Finkelstein JA, Pelton SI, Mitchell PK, Lee GM, Parkhill J, et al. Population

322 genomics of post-vaccine changes in pneumococcal epidemiology. Nat Genet

323 2013;45:656-663.

324 Dagan R. Serotype replacement in perspective. Vaccine 2009;27 Suppl 3:C22-C24.

325   Del AE, Brotons P, Monsonis M, Trivino M, Inigo M, Selva L, et al. High invasiveness of

326   pneumococcal serotypes included in the new generation of conjugate vaccines. Clin

327   Microbiol Infect 2014;20:684-689.

328   Enright MC, Spratt BG. A multilocus sequence typing scheme for *Streptococcus pneumoniae*:

329   identification of clones associated with serious invasive disease. Microbiology

330   1998;144 (Pt 11):3049-3060.

331   Ho PL, Ang I, Chow KH, Lai EL, Chiu SS. The prevalence and characteristics of

332   *Streptococcus pneumoniae* isolates expressing serotypes 6C and 6D in Hong Kong

333   prior to the introduction of the 7-valent pneumococcal conjugate vaccine. Diagn

334   Microbiol Infect Dis 2010;68:439-444.

335   Ho PL, Chiu SS, Ang I, Lau YL. Serotypes and antimicrobial susceptibilities of invasive

336   *Streptococcus pneumoniae* before and after introduction of 7-valent pneumococcal

337   conjugate vaccine, Hong Kong, 1995-2009. Vaccine 2011a;29:3270-3275.

338   Ho PL, Chiu SS, Chan MY, Ang I, Chow KH, Lau YL. Changes in nasopharyngeal carriage

339   and serotype distribution of antibiotic-resistant *Streptococcus pneumoniae* before and

340   after the introduction of 7-valent pneumococcal conjugate vaccine in Hong Kong.

341   Diagn Microbiol Infect Dis 2011b;71:327-334.

342   Ho PL, Chiu SS, Cheung CH, Lee R, Tsai TF, Lau YL. Invasive pneumococcal disease

343   burden in Hong Kong children. Pediatr Infect Dis J 2006;25:454-455.

344   Levy C, Varon E, Picard C, Bechet S, Martinot A, Bonacorsi S, et al. Trends of

345   Pneumococcal meningitis in children after Introduction of the 13-valent pneumococcal

346   conjugate vaccine in France. Pediatr Infect Dis J 2014 (electronicaly published on 16

347   July 2014).

348   Li Y, Tomita H, Lv Y, Liu J, Xue F, Zheng B, et al. Molecular characterization of erm(B)-

349   and mef(E)-mediated erythromycin-resistant *Streptococcus pneumoniae* in China and

350   complete DNA sequence of Tn2010. J Appl Microbiol 2011;110:254-265.

351   Martin JM, Hoberman A, Paradise JL, Barbadora KA, Shaikh N, Bhatnagar S, et al.

352   Emergence of *Streptococcus pneumoniae* Serogroups 15 and 35 in nasopharyngeal

353   cultures from young children with acute otitis media. Pediatr Infect Dis J

354   2014;33:e286-e290.

355   Mehr S, Wood N. *Streptococcus pneumoniae*--a review of carriage, infection, serotype

356   replacement and vaccination. Paediatr Respir Rev 2012;13:258-264.

357   Miller E, Andrews NJ, Waight PA, Slack MP, George RC. Herd immunity and serotype

358   replacement 4 years after seven-valent pneumococcal conjugate vaccination in England

359   and Wales: an observational cohort study. Lancet Infect Dis 2011;11:760-768.

360   Moore MR, Gertz RE, Jr., Woodbury RL, Barkocy-Gallagher GA, Schaffner W, Lexau C, et

361   al. Population snapshot of emergent *Streptococcus pneumoniae serotype* 19A in the

362   United States, 2005. J Infect Dis 2008;197:1016-1027.

363   Pai R, Gertz RE, Beall B. Sequential multiplex PCR approach for determining capsular

364   serotypes of *Streptococcus pneumoniae* isolates. J Clin Microbiol 2006;44:124-131.

365   Scott JR, Hanage WP, Lipsitch M, Millar EV, Moulton LH, Hinds J, et al. Pneumococcal

366   sequence type replacement among American Indian children: a comparison of pre- and

367   routine-PCV7 eras. Vaccine 2012;30:2376-2381.

368   Wroe PC, Lee GM, Finkelstein JA, Pelton SI, Hanage WP, Lipsitch M, et al. Pneumococcal

369   carriage and antibiotic resistance in young children before 13-valent conjugate vaccine.

370   Pediatr Infect Dis J 2012;31:249-254.

371   Yildirim I, Hanage WP, Lipsitch M, Shea KM, Stevenson A, Finkelstein J, et al. Serotype

372   specific invasive capacity and persistent reduction in invasive pneumococcal disease.

373   Vaccine 2010;29:283-288.

374   Zuccotti G, Mameli C, Daprai L, Garlaschi ML, Dilillo D, Bedogni G, et al. Serotype

375   distribution and antimicrobial susceptibilities of nasopharyngeal isolates of

376   *Streptococcus pneumoniae* from healthy children in the 13-valent pneumococcal

377   conjugate vaccine era. Vaccine 2014;32:527-534.

378
379
380

381   **Figure S1. eBURST analysis showing the ST distribution of serogroup 15 isolates.** A

382   total of 849 serogroup 15 isolates including 767 isolates from the MLST database (accessed

383   on 25 August 2014) and 82 isolates form the current study were included. The four major

384   clonal clusters (CC) found in this study were indicated with arrows.

385
386

387
388
389